Xilio Therapeutics is a clinical-stage biotechnology company that is focused on developing targeted immunotherapies for patients with cancer. The company's proprietary technology platform is designed to enhance the immune system's ability to recognize and attack cancer cells. Xilio's lead product candidate, XTX101, is a tumor-selective IL-2 agonist that is being developed for the treatment of solid tumors. The company is headquartered in Cambridge, Massachusetts.